Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-04-17

Clinical Trial Update: Belimumab in Remission of VASculitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating belimumab for inducing remission in vasculitis has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belimumab (belimumab)

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Vasculitis | Phase 3 | Status: COMPLETED | Results posted: 2018-04-17